Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Japan Tissue Engineering Co's Revenue for the
six
months ended in Mar. 2026 was 円1,184 Mil. Japan Tissue Engineering Co's average Accounts Receivable for the
six
months ended in Mar. 2026 was 円433 Mil.
Hence, Japan Tissue Engineering Co's Receivables Turnover for the
six
months ended in Mar. 2026 was 2.73.
Japan Tissue Engineering Co (TSE:7774) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Japan Tissue Engineering Co Receivables Turnover Related Terms
Japan Tissue Engineering Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co Receivables Turnover Chart
TSE:7774 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co (TSE:7774) has a Receivables Turnover of 2.73 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Japan Tissue Engineering Co and its competitors. According to the industry distribution chart, Japan Tissue Engineering Co ranks #471 out of 841 companies in the Biotechnology industry, placing it in the top 56%.
Is Japan Tissue Engineering Co's Receivables Turnover too high?
Japan Tissue Engineering Co's current Receivables Turnover is 2.73. The Biotechnology industry median Receivables Turnover is 5.29. Japan Tissue Engineering Co's value of 2.73 is 48.4% below this industry median. Based on the distribution chart, Japan Tissue Engineering Co ranks #471 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #471 out of 841 companies for Receivables Turnover. This places Japan Tissue Engineering Co in the lower half of its industry. The industry median Receivables Turnover is 5.29. Japan Tissue Engineering Co's value of 2.73 is 48.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Tissue Engineering Co's current Receivables Turnover of 2.73 is 48.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Japan Tissue Engineering Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Tissue Engineering Co's current Receivables Turnover is 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.88, compared to a current price of 円675.00 — trading 30.3% above its estimated fair value. The current Receivables Turnover is 2.73 and 48.4% below the Biotechnology industry median of 5.29. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Receivables Turnover is 2.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円675.00 is trading 30.3% above its estimated GF Value™ of 円517.88.
GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.
Key valuation signals for TSE:7774:
Receivables Turnover: 2.73
GF Value™: 円517.88 vs. price of 円675.00 (30.3% above fair value)
Industry Position: 48.4% below the Biotechnology median (#471 of 841)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score
Get the complete analysis for TSE:7774
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
